Axsome Therapeutics Inc. (AXSM)
Axsome Therapeutics Statistics
Share Statistics
Axsome Therapeutics has 48.77M shares outstanding. The number of shares has increased by 2.67% in one year.
Shares Outstanding | 48.77M |
Shares Change (YoY) | 2.67% |
Shares Change (QoQ) | 0.63% |
Owned by Institutions (%) | 77.28% |
Shares Floating | 40.08M |
Failed to Deliver (FTD) Shares | 8 |
FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 5.15M, so 10.56% of the outstanding shares have been sold short.
Short Interest | 5.15M |
Short % of Shares Out | 10.56% |
Short % of Float | 12.63% |
Short Ratio (days to cover) | 9.16 |
Valuation Ratios
The PE ratio is -14.11 and the forward PE ratio is 42.99. Axsome Therapeutics's PEG ratio is -1.03.
PE Ratio | -14.11 |
Forward PE | 42.99 |
PS Ratio | 10.51 |
Forward PS | 1.9 |
PB Ratio | 71.1 |
P/FCF Ratio | -31.5 |
PEG Ratio | -1.03 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Axsome Therapeutics.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.11, with a Debt / Equity ratio of 3.36.
Current Ratio | 2.11 |
Quick Ratio | 2.04 |
Debt / Equity | 3.36 |
Debt / EBITDA | -0.68 |
Debt / FCF | -1.49 |
Interest Coverage | -42.71 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $564.7K |
Profits Per Employee | $-420.52K |
Employee Count | 683 |
Asset Turnover | 0.68 |
Inventory Turnover | 2.12 |
Taxes
Income Tax | 85K |
Effective Tax Rate | -0.03% |
Stock Price Statistics
The stock price has increased by 44.88% in the last 52 weeks. The beta is 0.88, so Axsome Therapeutics's price volatility has been higher than the market average.
Beta | 0.88 |
52-Week Price Change | 44.88% |
50-Day Moving Average | 118.82 |
200-Day Moving Average | 97.93 |
Relative Strength Index (RSI) | 40.18 |
Average Volume (20 Days) | 1.02M |
Income Statement
In the last 12 months, Axsome Therapeutics had revenue of 385.69M and earned -287.22M in profits. Earnings per share was -5.99.
Revenue | 385.69M |
Gross Profit | 352.39M |
Operating Income | -280.56M |
Net Income | -287.22M |
EBITDA | -280.56M |
EBIT | -280.56M |
Earnings Per Share (EPS) | -5.99 |
Balance Sheet
The company has 315.35M in cash and 191.53M in debt, giving a net cash position of 123.82M.
Cash & Cash Equivalents | 315.35M |
Total Debt | 191.53M |
Net Cash | 123.82M |
Retained Earnings | -1.12B |
Total Assets | 568.5M |
Working Capital | 254.96M |
Cash Flow
In the last 12 months, operating cash flow was -128.41M and capital expenditures -270K, giving a free cash flow of -128.68M.
Operating Cash Flow | -128.41M |
Capital Expenditures | -270K |
Free Cash Flow | -128.68M |
FCF Per Share | -2.69 |
Margins
Gross margin is 91.37%, with operating and profit margins of -72.74% and -74.47%.
Gross Margin | 91.37% |
Operating Margin | -72.74% |
Pretax Margin | -74.45% |
Profit Margin | -74.47% |
EBITDA Margin | -72.74% |
EBIT Margin | -72.74% |
FCF Margin | -33.36% |
Dividends & Yields
AXSM does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for AXSM is $167, which is 62.1% higher than the current price. The consensus rating is "Buy".
Price Target | $167 |
Price Target Difference | 62.1% |
Analyst Consensus | Buy |
Analyst Count | 15 |
Scores
Altman Z-Score | 2.79 |
Piotroski F-Score | 3 |